Your browser doesn't support javascript.
loading
Qualifying coronavirus disease 2019 convalescent plasma donors in Israel.
Izak, Marina; Gendelman, Veronica; Bransburg-Zabary, Sharron; Stoyanov, Evgeniy; Gat, Roni; Cohen, Daniel; Chen, Jacob; Maor, Yasmin; Benov, Avi; Lev, Boaz; Zimhony, Oren; Shinar, Eilat.
Afiliação
  • Izak M; National Blood Services, Magen David Adom, Ramat Gan, Israel.
  • Gendelman V; National Blood Services, Magen David Adom, Ramat Gan, Israel.
  • Bransburg-Zabary S; National Blood Services, Magen David Adom, Ramat Gan, Israel.
  • Stoyanov E; National Blood Services, Magen David Adom, Ramat Gan, Israel.
  • Gat R; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
  • Cohen D; Clinical Research Center, Soroka University Medical Center, Beer Sheva, Israel.
  • Chen J; School of Public Health, Tel Aviv University, Tel Aviv, Israel.
  • Maor Y; Trauma and Combat Medicine Branch, Israel Defense Forces Medical Corps, Ramat Gan, Israel.
  • Benov A; Hospital Management, Meir Medical Center, KfarSaba, Israel.
  • Lev B; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Zimhony O; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Shinar E; Infectious Disease Unit, Wolfson Medical Center, Holon, Israel.
Vox Sang ; 117(2): 185-192, 2022 Feb.
Article em En | MEDLINE | ID: mdl-34125976
BACKGROUND AND OBJECTIVES: Passive immunization using investigational COVID-19 convalescent plasma (CCP) is a promising therapeutic strategy and could improve outcome if transfused early and contain high levels of anti-SARS-CoV-2 antibodies. We report the management of a national CCP collection and distribution program in Israel. MATERIALS AND METHODS: From 1 April 2020 to 15 January 2021, 4020 volunteer donors donated 5221 CCP units and 837 (20.8%) donors donated more than once. Anti-nucleocapsid IgG antibodies were determined using chemiluminescent immunoassay method (Abbott). A statistical model based on repeated IgG tests in sequential donations was created to predict the time of antibody decline below sample/cut-off (S/CO) level of 4.0. RESULTS: Ninety-six percent of CCP donors suffered a mild disease or were asymptomatic. Older donors had higher antibody levels. Higher antibody levels (S/CO ≥4) were detected in 35.2% of the donors. Low positive (S/CO ≥1.4-3.99) were found in 37%, and 27.8% had undetectable antibodies (S/CO ≤1.4). The model predicted decrease antibody thresholds of 0.55%/day since the first CCP donation, providing guidance for the effective timing of future collections from donors with high antibody levels. CONCLUSIONS: An efficient CCP collection and distribution program was achieved, based on performing initial and repeated plasma collections, preferably from donors with higher antibody levels, and only antibody-rich units were supplied for therapeutic use. The inventory met the quantity and quality standards of the authorities, enabled to respond to the growing demand of the medical system and provide a product that may contribute to improve prognosis in patients with COVID-19.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Guideline / Prognostic_studies Limite: Humans País/Região como assunto: Asia Idioma: En Revista: Vox Sang Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Israel

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Guideline / Prognostic_studies Limite: Humans País/Região como assunto: Asia Idioma: En Revista: Vox Sang Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Israel